Sector
PharmaceuticalsOpen
₹50.15Prev. Close
₹49.98Turnover(Lac.)
₹565.37Day's High
₹54.7Day's Low
₹49.9552 Week's High
₹129.4452 Week's Low
₹48.73Book Value
₹23.16Face Value
₹2Mkt Cap (₹ Cr.)
276.31P/E
77EPS
0.65Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.67 | 20.48 | 10 | 10 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 106.88 | 71.63 | 47.91 | 33.25 |
Net Worth | 121.55 | 92.11 | 57.91 | 43.25 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 101.29 | 86.87 | 45.63 | 0 |
yoy growth (%) | 16.59 | 90.37 | 0 | 0 |
Raw materials | -76.91 | -63.32 | -33.57 | 0 |
As % of sales | 75.93 | 72.89 | 73.58 | 0 |
Employee costs | -2.89 | -1.94 | -1.76 | -0.15 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 19.69 | 20.59 | 9.26 | -0.76 |
Depreciation | -0.25 | -0.08 | 0 | 0 |
Tax paid | -5.03 | -5.46 | -2.76 | 0 |
Working capital | 5.53 | -0.38 | 25.39 | -0.78 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.59 | 90.37 | 0 | 0 |
Op profit growth | -8.6 | 192.29 | -941.06 | 471.3 |
EBIT growth | -4.12 | 122.43 | -1,303.49 | 478.82 |
Net profit growth | -3.07 | 132.97 | -943.73 | 341.95 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 292.56 | 241.29 | 336.43 | 279.39 | 231.33 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 292.56 | 241.29 | 336.43 | 279.39 | 231.33 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | -3.72 | -2.65 | 2.64 | 4.97 | 2.23 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Ashish Maheshwari
Non Executive Director
Minoshi Maheshwari
Independent Non Exe. Director
Kunal M Bhakta
Independent Non Exe. Director
Gandhi Gamji
Independent Non Exe. Director
M. Srinivas Rao
Company Sec. & Compli. Officer
Mohith Kumar Khandelwal
41/298-D2 2nd Flr Saniya Plaza,
Mahakavi Bharatiyar Road,
Kerala - 682035
Tel: 91-484-4032952/6596725
Website: http://www.balaxipharma.in
Email: [email protected]
Surya 35 Mayflower,
Avenue Sowripalayam, Road,
Coimbatore - 641 028
Tel: 91-422-4958995/836
Website: www.skdc-consultants.com
Email: [email protected]
Summary
Balaxi Ventures Limited was formerly incorporated in the name of The Anandam Rubber Company Limited on September 28, 1942. The Company changed its name from The Anandam Rubber Company Limited to Balax...
Read More
Reports by Balaxi Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.